Liver Cancer Trial, Recruiting NCT05428735 Sponsor: Maastricht University Condition: Liver Cancer
Back to Liver Cancer

Liver Cancer Trial, Recruiting

NCT05428735
Recruiting Not Applicable 🇦🇺 Australian site

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have colorectal cancer that has spread to the liver (liver metastases) that cannot currently be fully removed by surgery, or may only potentially be removable, and where the remaining healthy liver after surgery would be too small (less than 30%, or less than 40% if the liver has been damaged by chemotherapy)
  • People whose original bowel cancer has not yet been surgically removed, if the medical team plans to remove it either after the liver treatment or at the same time as one of the liver procedures
  • People who also have cancer that has spread to the lungs or brain, if a specialist medical team has confirmed those secondary cancers can be removed by surgery or destroyed by other means
  • People aged 18 years and older
  • Both men and women
  • People who are able to understand the trial and agree in writing to take part

Who may not be able to join:

  • People who are pregnant or currently breastfeeding
  • Women who have not yet reached menopause and are unwilling or unable to use oral contraception during the trial
  • People with serious other health conditions that the local medical team considers too risky (confirm with trial site)
  • People who have cancer that has spread outside the liver and cannot be removed by surgery or destroyed by other means
  • People who have a type of liver cancer other than colorectal cancer that has spread to the liver
  • People whose cancer continued to grow or spread during chemotherapy given to shrink the tumours before surgery
  • People whose cancer completely disappeared in response to chemotherapy given to make the tumours operable
  • People whose scans (CT, and brain CT or MRI if needed) show cancer spread outside the liver that cannot be removed or destroyed
  • People whose liver shape, structure, or the position of tumours near major liver veins makes the specific combined procedure used in this trial (a technique involving two types of vein procedures) not possible

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 21 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Ronald M. van Dam, PhD, Maastricht Universitair Medisch Centrum

Phone: +31 638463945

Australian sites

Monash Medical Centre, Clayton, Victoria

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Maastricht University
Registry
ClinicalTrials.gov
Start date
1 April 2022
Est. completion
30 June 2026

Where this trial is recruiting

🇦🇺 Australia 🇦🇹 Austria 🇧🇪 Belgium 🇨🇦 Canada 🇮🇹 Italy 🇳🇱 Netherlands 🇸🇪 Sweden 🇨🇭 Switzerland 🇺🇸 United States

1 site(s) in Australia. Confirm current status and contact details directly with the trial site.

Primary endpoints

Volume sufficient for resection at week 3 after the embolization; 5-year Overall Survival

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov